2025年财务展望

公司发布了2025年的展望，摘要如下：

• 2025年的收入将在108.5亿美元至111.5亿美元之间
• 2025年的调整后EBITDA将在5.60亿美元至5.90亿美元之间
• 2025年的调整后每股收益将在1.60美元至1.85美元之间

公司的2025年展望不包括之前宣布的Rotech收购、与产品和医疗服务部门有关的任何潜在交易或股票回购活动的影响，并包含了对当前经济状况影响的预期。

支持公司2025年财务指导的关键假设包括：

• 毛利率在20.75%至21.25%之间
• 利息支出在1.38亿美元至1.42亿美元之间
• 调整后的有效税率在29.0%至30.0%之间
• 稀释后的加权平均股份约为8000万股
• 资本支出（毛额）在2.50亿美元至2.70亿美元之间
• 商品价格稳定
• 截至2024年12月31日的外汇汇率

2025 Financial Outlook

The Company issued its outlook for 2025; summarized below:

• Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion
• Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million
• Adjusted EPS for 2025 to be in a range of $1.60 to $1.85

The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products & Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.

Key assumptions supporting the Company's 2025 financial guidance include:

• Gross margin of 20.75% to 21.25%
• Interest expense of $138 million to $142 million
• Adjusted effective tax rate of 29.0% to 30.0%
• Diluted weighted average shares of ~80 million
• Capital expenditures, gross, of $250 million to $270 million
• Stable commodity prices
• FX rates as of 12/31/2024